FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1160-1174 March 13, 2008 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article

Cancer cells may acquire the capacity for autonomous and dysregulated proliferation through the uncontrolled production of specific molecules that promote cell growth (growth factors) or through abnormal, enhanced expression of specific proteins (growth factor receptors) on the cell membranes to which growth factors selectively bind. Both processes trigger a series of intracellular signals that ultimately lead to the proliferation of cancer cells, induction of angiogenesis, and metastasis.¹ The majority of human epithelial cancers are marked by functional activation of growth factors and receptors of the epidermal growth factor receptor (EGFR) family. Given this phenomenon, EGFR was the first growth factor . . . [Full Text of this Article]

EGFR in Human Carcinogenesis

Development of EGFR Antagonists for Anticancer Therapy

Clinical Efficacy of EGFR Antagonists in Human Cancers

Non–Small-Cell Lung Cancer

Colorectal Cancer

Squamous-Cell Carcinoma of the Head and Neck

Pancreatic Cancer

Predicting the Response to Anti-EGFR Drugs

Clinical and Pathological Predictors

EGFR Protein Expression

Somatic EGFR Gene Mutations

Increased EGFR Copy Number

Resistance to EGFR Antagonists

Intrinsic Resistance

Acquired Resistance

Future Directions

Source Information

From the Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples (F.C.); and the Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II (G.T.) — both in Naples, Italy.

Address reprint requests to Dr. Ciardiello at the Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples, Via S. Pansini 5, 80131 Naples, Italy, or at fortunato.ciardiello@unina2.it.

This article has been cited by other articles:

• Berasain, C., Perugorria, M. J., Latasa, M. U., Castillo, J., Goni, S., Santamaria, M., Prieto, J., Avila, M. A. (2009). The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer. Exp. Biol. Med. 234: 713-725 [Abstract] [Full Text]  
• Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., Michotte, A., De Greve, J. (2009). Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 0: mdp032v1-mdp032 [Abstract] [Full Text]  
• RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]  
• Herberger, B., Berger, W., Puhalla, H., Schmid, K., Novak, S., Brandstetter, A., Pirker, C., Gruenberger, T., Filipits, M. (2009). Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Molecular Cancer Therapeutics 8: 1547-1556 [Abstract] [Full Text]  
• Nowak, D., Stewart, D., Koeffler, H. P. (2009). Differentiation therapy of leukemia: 3 decades of development. Blood 113: 3655-3665 [Abstract] [Full Text]  
• Chen, Y., Lu, B., Yang, Q., Fearns, C., Yates, J. R. III, Lee, J.-D. (2009). Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA-Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration. Cancer Res. 69: 3713-3720 [Abstract] [Full Text]  
• Xian, W., Pappas, L., Pandya, D., Selfors, L. M., Derksen, P. W., de Bruin, M., Gray, N. S., Jonkers, J., Rosen, J. M., Brugge, J. S. (2009). Fibroblast Growth Factor Receptor 1-Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival. Cancer Res. 69: 2244-2251 [Abstract] [Full Text]  
• Smallridge, R. C, Marlow, L. A, Copland, J. A (2009). Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44 [Abstract] [Full Text]  
• Benavente, S., Huang, S., Armstrong, E. A., Chi, A., Hsu, K.-T., Wheeler, D. L., Harari, P. M. (2009). Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clin. Cancer Res. 15: 1585-1592 [Abstract] [Full Text]  
• Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P. L., Biasco, G. (2009). Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 20: 213-226 [Abstract] [Full Text]  
• Memon, A. A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B. S., Keiding, S., Nexo, E. (2009). Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts. Cancer Res. 69: 873-878 [Abstract] [Full Text]  
• Anastasia, L., Papini, N., Colazzo, F., Palazzolo, G., Tringali, C., Dileo, L., Piccoli, M., Conforti, E., Sitzia, C., Monti, E., Sampaolesi, M., Tettamanti, G., Venerando, B. (2008). NEU3 Sialidase Strictly Modulates GM3 Levels in Skeletal Myoblasts C2C12 Thus Favoring Their Differentiation and Protecting Them from Apoptosis. J. Biol. Chem. 283: 36265-36271 [Abstract] [Full Text]  
• Chen, P.-H., Yang, C.-R. (2008). Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-{kappa}B-Dependent Pathway. J. Immunol. 181: 8441-8449 [Abstract] [Full Text]  
• Neupane, D., Korc, M. (2008). 14-3-3{sigma} Modulates Pancreatic Cancer Cell Survival and Invasiveness. Clin. Cancer Res. 14: 7614-7623 [Abstract] [Full Text]  
• Herbst, R. S., Heymach, J. V., Lippman, S. M. (2008). Lung Cancer. NEJM 359: 1367-1380 [Full Text]  
• Haluska, P., Carboni, J. M., TenEyck, C., Attar, R. M., Hou, X., Yu, C., Sagar, M., Wong, T. W., Gottardis, M. M., Erlichman, C. (2008). HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Molecular Cancer Therapeutics 7: 2589-2598 [Abstract] [Full Text]  
• Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., Albini, A., Ryan, A., Ciardiello, F., Tortora, G. (2008). Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clin. Cancer Res. 14: 5069-5080 [Abstract] [Full Text]